HER2-positive invasive breast carcinoma (NST). HER2 gene-protein assay: brightfield tricolor assay (combined ICH+ISH) for the visualization of HER2 protein (brown), the HER2 gene (black), and chromosome 17 centromere (CEN17) (red).

This helpful infographic from National Human Genome Research Institute explains the challenges of sequencing highly repetitive DNA and the technological advances that were needed to generate the first truly complete (gapless) human genome sequence. I encourage you to check it out! genome.gov/about-genomics…

.Toni Choueiri, MD takes the stage to present data from the phase 1 ARC-20 trial that shows that the combination of HIF2 inhibitor casdatifan plus cabo has promising clinical activity (cORR 46%) and an acceptable safety profile in pretreated pts w/ mRCC. #ASCO25 ASCO OncoAlert

🎯 Too many targets. Too little time. ⏳ On June 11, 2025, Taletrectinib received FDA approval for advanced ROS1+ NSCLC. With impressive ORR and CNS activity, it reshapes the ROS1 landscape. 🧠 To keep track of all genetically driven NSCLC therapies, we created this clean,

📢 A new era in head & neck cancer care begins. #FDA approves #pembrolizumab as the first immunotherapy for perioperative use in resectable LA-HNSCC. Neoadjuvant + adjuvant strategy now reshapes standard of care. 👇See the full breakdown: 📊 #KEYNOTE689 | 📆 June 12, 2025

A comprehensive review about the role of tumor microenvironment on the immunotherapy response! OncoAlert Nature Cancer #Cancer #Oncology #MedTwitter nature.com/articles/s4301…

🎯 Testicular cancer is the most common solid tumor in young men (15–40y), with >90% being germ cell tumors (GCTs). Early diagnosis + tailored treatment = excellent outcomes (5y OS: 99% in stage I). Survivorship matters 👉🏻 fertility, CV risk & QoL must guide care. 📖

𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬𝟗 is a process in which clustered regularly interspaced short palindromic repeats (CRISPR) — small remnants of viral DNA from previous viral infection that are embedded in bacterial DNA — generate guide RNAs, which are used together with a DNA-cutting enzyme

Advances in molecular pathology and therapy of non-small cell lung cancer 💫An exceptionally comprehensive review (72 pages 👀) Algorithms👇 nature.com/articles/s4139…

Unique pattern of an uncommon #testis tumor. What’s is your diagnosis #GUPath tweeps? #OnePicDx Answer in comment👇👇👇

Big news! Massachusetts General Hospital and Brigham and Women’s Hospital have been ranked #1 and #2 globally for research impact among healthcare institutions by the 2024 Nature Index. Proud to be part of a pathology department at the forefront of discovery! 🧪🔬 #PathTwitter

Assessment and classification of sex cord‐stromal tumours of the testis: recommendations from the testicular sex cord‐stromal tumour (TESST) group, an Expert Panel of GUPS and ISUP- Acosta - Histopathology - Wiley Online Library #openaccess onlinelibrary.wiley.com/doi/10.1111/hi…

🧾 Cheat Sheet on Follow-up for NMIBC 🔹 Risk-based surveillance 🔹 Lifelong follow-up for high-risk patients 🔹 Role of cytology & markers 🔍 No substitute for cystoscopy Download Cheat Sheet: uroweb.org/guidelines/non… #BladderCancer #NMIBC #EAUguidelines

Enjoy Kidney Cancer's Special Pathology Edition. A great set of [open access] RCC reviews; also, sarcomas, benign tumors, molecular changes, familial syndromes, grading/staging. Great for patients, clinicians, researchers & pathologists.🔬#gupath UroToday.com journals.sagepub.com/toc/kcaa/9/1_s…

Molecular and Therapeutic Landscape of Non-Clear Cell Renal Cell Carcinoma: 🧬🧬🧬Diverse subtypes, unique genetics, unpredictable responses. Nature Reviews Urology OncoAlert KidneyCAN IKCC Kidney Cancer Kidney Cancer Reza Mehrazin, MD rdcu.be/ewjT8

Insightful discussions, cutting edge research, great speakers, multidisciplinary approach & an amazing audience- perfect #kidneycancer meeting KidneyCAN #KCRS2025 #genomics #pathology #cancer

So proud to be part of this incredible research team! #KCRS25 #pathology #kidneycancer KidneyCAN

Ovarian Cancer jamanetwork.com/journals/jama/…

60s M with a renal mass. What is your diagnosis? #PathTwitter Mass General Brigham Pathology MGH Pathology

Some prostate cancers evade therapy by transforming into aggressive neuroendocrine prostate cancer. New research highlights PROX1 as a key driver of this transformation and tumor growth, offering a potential treatment target. ➡️ bit.ly/4lEFHoD Cancer Research @bajji